CTLA4 and small cell lung carcinoma: Although immunotherapy has made great progress in the treatment of SCLC patients, there have been limited improvements in survival rates for SCLC patients with the current immune checkpoint inhibitors PD-1/PD-L1 and CTLA-4 [129].